Seedlabs

Retinal E/I Stratification Kit for Neurodevelopmental Drug Trials

A kit for drug trials that groups participants by how their eyes respond to light to find the best matches for new medicines.

A screening-site kit for autism and ADHD drug trials that measures each participant's retinal response and bands them into physiologically defined subgroups, so sponsors enroll more homogeneous, mechanistically matched cohorts.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderPharmaceutical clinical trials — biomarker stratification for neurodevelopmental (ASD/ADHD) drug studies

Concept

A standardized site kit for neurodevelopmental drug trials (autism and ADHD): a nine-flash, light-adapted ERG protocol run at participating screening sites, with centralized reading and banding. Each participant's b-wave amplitude at 1.204 log photopic cd.s.m−2 (plus PhNR and time-to-peak) is scored into elevated / typical / reduced retinal-response bands, giving sponsors a physiological stratification axis at enrollment — for example, enriching a glutamate/GABA-targeted autism trial with the reduced-b-wave subgroup, or balancing randomization across bands. Because retinal testing takes minutes, is well tolerated by children, and can be repeated at every visit, the same measure doubles as a low-burden longitudinal characterization readout across a trial. Unlike symptom-profile-based trial recruitment, this stratifies cohorts on an objective physiological measure. The kit ships with banding thresholds calibrated on the published group means and standard deviations, then refined on the sponsor's own screening data; the offering is a per-trial service (kit + central readout + report).

Why now

The source study [0] demonstrates that a single retinal measure separates neurodevelopmental conditions physiologically: at the top flash strength, b-wave amplitude was 37.2 ± 10.3 μV in ADHD vs 24.7 ± 8.9 μV in ASD (controls 28.2 ± 8.6 μV), distinguishing ADHD from ASD with an AUC of 0.88, with corroborating PhNR and time-to-peak differences. The authors interpret the b-wave differences as imbalances in glutamate and GABA neurotransmission — precisely the systems targeted by experimental neurodevelopmental drugs, which gives the stratification mechanistic face validity. The marker also appeared stable under stimulant medication in the tested participants, reducing co-medication confounding, a practical concern in any trial that enrolls treated ADHD participants. Sizing to readiness: the group separation was shown in 131 participants (15 ADHD / 57 ASD / 59 controls), so the kit is positioned for exploratory stratification with thresholds refined per study, not as a validated enrichment biomarker out of the box.

Written by GLM · 10 Oct 2026

AI assessment

Backed by 1 paper82

A high-value, focused application of ERG biomarkers to solve the 'heterogeneity problem' in neurodevelopmental drug trials, though it is a direct commercial pivot of an existing diagnostic idea.

Evidence strength
4/5
The full-text data provides specific b-wave amplitudes and a strong AUC (0.88) for distinguishing ASD from ADHD, supporting the physiological basis for stratification.
Market pull
5/5
Pharmaceutical sponsors have a massive financial incentive to reduce trial failure rates by enrolling mechanistically homogeneous cohorts, making this a high-urgency B2B sale.
Novelty & moat
2/5
The core mechanism and user are nearly identical to the 'B-Wave Split' idea; it simply shifts the value proposition from clinical diagnosis to trial stratification.
Feasibility
4/5
ERG is a standard clinical procedure; the 'kit' is essentially a standardized protocol and a centralized data analysis pipeline, which is highly feasible.
Wedge clarity
5/5
The wedge is extremely sharp: a per-trial service for a specific set of drug sponsors targeting glutamate/GABA pathways.
Simplicity / focus
5/5
The idea avoids 'platform' creep, focusing strictly on a single measurement (ERG) for a single purpose (stratification).

Scored by Gemma 4 · 10 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • STALICLAcompany

    Swiss precision-medicine biotech that already stratifies people with ASD by biomarker clusters for its clinical programs; a low-burden retinal stratification axis directly extends that platform.

  • Mapregcompany

    Develops bumetanide-based treatments targeting GABAergic function in neurodevelopmental disorders; a retinal readout that proxies glutamate/GABA balance offers a mechanistically matched stratification and tracking measure.

  • Simons Foundation (SPARK)organization

    Runs the largest autism research registry; adding a 15-minute ERG would let it offer research partners physiologically characterized sub-cohorts for study enrollment.

  • IQVIAcompany

    Global CRO operating neurodevelopmental trial sites; a standardized site kit with a central readout is a deployable stratification service across its site network.

Research it builds on

  1. The electroretinogram b-wave amplitude: a differential physiological measure for Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder
    Irene Lee, David Skuse, Paul A. Constable et al. · 2022 · 44 citations
    All ideas from this paper →
Leave feedback
feasibility